{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-309581","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2022-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.890226+00:00","generated_at":"2026-06-21T00:41:44.885857+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Jazz exercises zanidatamab option; pays $325M; 41.3% ORR in BTC trial","bullets":["Jazz exercised option to retain exclusive rights to zanidatamab in U.S., Europe, and Japan.","One-time $325M payment in Q4 2022; total potential milestones up to $1.76B plus royalties.","Pivotal HERIZON-BTC-01 trial showed 41.3% ORR (95% CI: 30.4-52.8) and median DOR 12.9 months.","Safety profile consistent with prior monotherapy; no new safety signals.","Zymeworks eligible for tiered royalties of 10-20% on Jazz net sales pending approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-309581","json":"https://secwatch.observer/filing/0001193125-22-309581.json","markdown":"https://secwatch.observer/filing/0001193125-22-309581.md","text":"https://secwatch.observer/filing/0001193125-22-309581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000119312522309581/0001193125-22-309581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000119312522309581/d439594d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:41:44.885857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}